Bicara Therapeutics Inc. (BCAX) Institutional Ownership

Ownership Summary

Bicara Therapeutics Inc. (NASDAQ:BCAX) appears in 137 institutional 13F filings for the quarter ending December 2025.

• They owned 101.4% of outstanding stock in December 2025, up from 93.2% the prior quarter.
• They increased total shares held in Bicara Therapeutics by 20.83% from last quarter, and the number of investors in BCAX increased 63.1% annually.
• Activity in BCAX broke down as 89 buyers, 34 sellers, and 14 unchanged among 137 total holders.
• Combined, these investors held 55.32Mn shares in BCAX for December 2025, up by 9.53Mn shares quarter on quarter, and up 6.89Mn shares year over year.
• RA CAPITAL MANAGEMENT, L.P. leads ownership in BCAX with 6.96Mn shares as of December 31, 2025, equal to 12.75% of outstanding shares.
• The most significant purchases of BCAX for the quarter ending December 2025 came from T. Rowe Price Investment Management, Inc. (2.94Mn), Janus Henderson Group Plc (2.65Mn), Franklin Resources Inc (1.62Mn), State Street Corp (1.06Mn), CITADEL ADVISORS LLC (772.26K).
• Top sellers of BCAX stock for the quarter ending December 2025 included Vestal Point Capital, LP (1.52Mn), MILLENNIUM MANAGEMENT LLC (580.19K), Bank Of America Corp /De/ (577.56K), Napean Trading & Investment Co (Singapore) PTE Ltd (162.16K), Woodline Partners LP (116.0K).
• Bicara Therapeutics's 10 largest shareholders as of December 2025 include RA CAPITAL MANAGEMENT, L.P. (6.96Mn), Siren, L.L.C. (5.22Mn), Vestal Point Capital, LP (3.58Mn), T. Rowe Price Investment Management, Inc. (3.4Mn), FMR LLC (3.35Mn), Red Tree Management, LLC (3.17Mn), TPG GP A, LLC (3.01Mn), Janus Henderson Group Plc (2.65Mn), Deep Track Capital, LP (2.61Mn), BlackRock, Inc. (2.53Mn) per Business Quant data.